News | Radiopharmaceuticals and Tracers | September 17, 2021

Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals

Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals

Getty Images


September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced its support of legislation recently introduced into the U.S. House of Representatives and the U.S. Senate. The bicameral, bipartisan bill, known as the “Facilitating Innovative Nuclear Diagnostics Act,” or the FIND Act of 2021 (H.R. 4479/S. 2609), would reform the current Medicare payment system to improve Medicare beneficiaries’ access to innovative technologies and safeguard appropriate payment to hospitals for innovative diagnostic radiopharmaceuticals.

The U.S. healthcare system relies on diagnostic imaging radiopharmaceuticals and nuclear medicine to inform patient management and assess disease severity and progression across a wide variety of medical conditions. According to the Society of Nuclear Medicine and Molecular Imaging (SNMMI), more than 20 million Americans benefit each year from nuclear medicine procedures.

Although diagnostic radiopharmaceuticals are appropriately defined by the U.S. Food and Drug Administration as drugs, the Centers for Medicare and Medicaid Services (CMS) categorizes them as “supplies” by packaging them, after an initial three-year period, alongside nuclear medicine services, into “bundles” for procedures that are conducted in hospital outpatient settings. Bundling payment often reimburses only a fraction of the actual cost of newer diagnostic radiopharmaceuticals and impedes the scientific advancement of new products that can help patients. Procedural bundling results in hospitals not receiving appropriate payment, and patients’ access to advanced diagnostic imaging radiopharmaceuticals may be restricted or denied. The FIND Act, if passed, would help give patients greater access to a wide range of advanced diagnostic radiopharmaceuticals for conditions such as prostate and breast cancers, heart disease, Alzheimer's and Parkinson’s disease, and neuroendocrine tumors.

“Blue Earth Diagnostics is the recognized leader in diagnostic PET prostate cancer imaging, and in line with our commitment to deliver innovative solutions that inform patient care, we fully support legislative passage of the FIND Act,” said Terri Wilson, President, Blue Earth Diagnostics, Inc. “The FIND Act can correct CMS payment policies to provide patients with equity in access and payment, and encourage ongoing development of targeted radiopharmaceuticals that can have transformative effects in patient lives.”

For more information: www.blueearthdiagnostics.com


Related Content

News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | SNMMI

June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...

Time June 13, 2024
arrow
News | PET-CT

June 13, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 13, 2024
arrow
News | Radiology Business

June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI, chair of the Isotope Research and Production Department at Brookhaven ...

Time June 12, 2024
arrow
News | SPECT-CT

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

Time June 11, 2024
arrow
News | PET Imaging

June 11, 2024 — A new ultra-high-performance brain PET system allows for the direct measurement of brain nuclei as never ...

Time June 11, 2024
arrow
News | Radiology Business

June 10, 2024 — Jean-Luc C. Urbain, MD, PhD, FASNC, professor of Radiology/Nuclear Medicine and Medicine, has been named ...

Time June 10, 2024
arrow
Subscribe Now